Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Absci Corporation (ABSI : NSDQ)

• Company Description    Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK. Number of Employees: 157

• Price / Volume Information    Yesterday's Closing Price: $3.45 Daily Weekly Monthly 20 Day Moving Average: 3,725,025 shares Shares Outstanding: 150.37 (millions) Market Capitalization: $518.78 (millions) Beta: 2.13 52 Week High: $6.33 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.49% 11.96% 12 Week -8.24% -10.44% Year To Date 31.68% 12.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18105 SE MILL PLAIN BLVD - VANCOUVER,WA 98683 USA ph: 360-949-1041 fax: - investors@absci.com http://www.absci.com

• General Corporate Information    Officers Sean McClain - Chief Executive Officer and Director Zachariah Jonasson - Chief Financial Officer Todd Bedrick - Chief Accounting Officer Frans van Houten - Director Karen McGinnis - Director Peer Information Absci Corporation (CORR.) Absci Corporation (RSPI) Absci Corporation (CGXP) Absci Corporation (BGEN) Absci Corporation (GTBP) Absci Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00091E109 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/17/26 Share - Related Items Shares Outstanding: 150.37 Most Recent Split Date: (:1) Beta: 2.13 Market Capitalization: $518.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.45 Price/Cash Flow: - Price / Sales: 184.29 EPS Growth vs. Year Ago Period: 16.67% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: -77.78% vs. Previous Quarter: -36.26% ROE 09/30/25 - -60.19 06/30/25 - -60.21 03/31/25 - -53.69 ROA 09/30/25 - -50.88 06/30/25 - -50.85 03/31/25 - -45.89 Current Ratio 09/30/25 - 5.89 06/30/25 - 4.39 03/31/25 - 5.72 Quick Ratio 09/30/25 - 5.89 06/30/25 - 4.39 03/31/25 - 5.72 Operating Margin 09/30/25 - -4,071.19 06/30/25 - -2,737.94 03/31/25 - -2,232.13 Net Margin 09/30/25 - -4,071.19 06/30/25 - -2,737.94 03/31/25 - -2,232.13 Pre-Tax Margin 09/30/25 - -4,062.24 06/30/25 - -2,733.47 03/31/25 - -2,231.01 Book Value 09/30/25 - 1.41 06/30/25 - 1.36 03/31/25 - 1.56 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.03 06/30/25 - 0.09 03/31/25 - 0.34

Powered by Zacks Investment Research ©